Two regulatory frameworks for compounding — and why it matters for peptide sourcing.
503A = individual prescriptions, state oversight, USP standards.
503B = batch production for office use, FDA oversight, cGMP standards.
| Factor | 503A | 503B |
|---|---|---|
| Oversight | State pharmacy board | FDA + state |
| Prescription required? | Yes, patient-specific | No (office use) |
| Quality standard | USP <795>/<797> | cGMP |
| Batch size | Individual quantities | Larger batches |
| Distribution | To patients/practitioners | To healthcare facilities |
| Adverse event reporting | State-level | FDA MedWatch |
503A if you’re a smaller practice, need custom formulations, or want flexibility with a local compounder.
503B if you’re high-volume, want to stock peptides for same-day administration, or value the extra layer of FDA oversight.
Some pharmacies (e.g., Empower) operate both divisions.
503B provides a higher regulatory floor, not a guarantee. A well-run 503A can outperform a poorly run 503B. Evaluate any pharmacy with the same rigor. Evaluation guide →